Cliff Asness’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-86,478
| Closed | -$127K | – | 2388 |
|
|
2022
Q2 | $127K | Sell |
86,478
-371,192
| -81% | -$273K | ﹤0.01% | 2057 |
|
|
2022
Q1 | $526K | Buy |
457,670
+439,427
| +2,409% | +$716K | ﹤0.01% | 1801 |
|
|
2021
Q4 | $46K | Buy |
+18,243
| New | +$71.7K | ﹤0.01% | 2178 |
|
|
2020
Q4 | – | Sell |
-61,825
| Closed | -$738K | – | 2289 |
|
|
2020
Q3 | $738K | Sell |
61,825
-52,381
| -46% | -$702K | ﹤0.01% | 1567 |
|
|
2020
Q2 | $1.83M | Sell |
114,206
-8,353
| -7% | -$146K | ﹤0.01% | 1193 |
|
|
2020
Q1 | $1.9M | Buy |
122,559
+84,575
| +223% | +$1.82M | ﹤0.01% | 1093 |
|
|
2019
Q4 | $934K | Buy |
37,984
+26,114
| +220% | +$388K | ﹤0.01% | 1534 |
|
|
2019
Q3 | $122K | Sell |
11,870
-11,555
| -49% | -$146K | ﹤0.01% | 2066 |
|
|
2019
Q2 | $294K | Buy |
+23,425
| New | +$301K | ﹤0.01% | 1884 |
|
|
2018
Q2 | – | Sell |
-14,894
| Closed | -$264K | – | 2404 |
|
|
2018
Q1 | $264K | Sell |
14,894
-12,980
| -47% | -$219K | ﹤0.01% | 2070 |
|
|
2017
Q4 | $350K | Sell |
27,874
-4,818
| -15% | -$70K | ﹤0.01% | 2023 |
|
|
2017
Q3 | $623K | Buy |
32,692
+6,808
| +26% | +$104K | ﹤0.01% | 1864 |
|
|
2017
Q2 | $391K | Buy |
+25,884
| New | +$391K | ﹤0.01% | 1972 |
|
Other funds holding EPZM
Cliff Asness's EPZM Position: Q3 2022 in Review
Cliff Asness sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 86,478 shares — an estimated $127K sold.
Cliff Asness first reported a position in EPZM in Q2 2017 and held it in 13 quarters. The position peaked at $1.9M in Q1 2020. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- Cliff Asness reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- Cliff Asness sold 86,478 Epizyme, Inc shares in Q3 2022, an estimated $127K.
- Cliff Asness first reported a position in Epizyme, Inc in Q2 2017 and held it in 13 quarters.
- Cliff Asness's Epizyme, Inc position peaked at $1.9M in Q1 2020.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on AQR Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.